Clinical Trial Update: Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Gemcitabine and Oxaliplatin (GEMOX) as first-line treatment for metastatic or recurrent nasopharyngeal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)

Snippet

Sponsor: Sanofi | Conditions: Nasopharyngeal Neoplasms | Phase 2 | Status: COMPLETED